QT
FDMT icon

Quantbot Technologies’s 4D Molecular Therapeutics FDMT Stock Holding History

Quantbot Technologies’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,421
Closed -$9K – 1730
2022
Q2 		$9K Buy
+1,421
New +$13.8K ﹤0.01% 1537

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quantbot Technologies's FDMT Position: Q3 2022 in Review

Quantbot Technologies sold out of 4D Molecular Therapeutics (FDMT) in Q3 2022, closing a stake of 1,421 shares — an estimated $9K sold.

Quantbot Technologies first reported a position in FDMT in Q2 2022 and held it in 1 quarter. The position peaked at $9K in Q2 2022. 88 funds tracked by Wall St. Rank hold FDMT as of Q3 2022.

  • Quantbot Technologies reported no remaining 4D Molecular Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Quantbot Technologies sold 1,421 4D Molecular Therapeutics shares in Q3 2022, an estimated $9K.
  • Quantbot Technologies first reported a position in 4D Molecular Therapeutics in Q2 2022 and held it in 1 quarter.
  • Quantbot Technologies's 4D Molecular Therapeutics position peaked at $9K in Q2 2022.
  • 88 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2022.

Based on Quantbot Technologies's 13F filing for Q3 2022, filed 7 Nov 2022.